Reply to Ross et al. We thank Ross et al. 1 for their additional comments on the definition of sensitivity with regard to minimal residual disease (MRD) in leukemia. Ross et al. 1 highlight two important issues that have to be addressed when estimating the lower limit of detection of MRD by a PCR assay: (1) the amount of DNA or RNA in each assay, and the number of replicates performed; and (2) the quality of the individual sample analysed.
We fully agree with these comments and the calculations that are provided by Ross et al. However, we would still challenge the statement that the standardized reporting of the estimated lower limit of detection of PCR assays for leukemia MRD is highly desirable. In clinical practice, we will always define a threshold of MRD that we use for therapeutic decisions, that is, if the MRD in a patient is above this threshold, we will perform a more intensive treatment than in another patient with an MRD below this threshold. 2 If we compare two different methods of monitoring MRD, the relevant question is to determine how reliably we can classify patients as having an MRD above or below this threshold. We have to determine the test sensitivity and specificity of the assays at this threshold.
The lower limit of detection of an MRD assay certainly provides some information about this assay, but the lower limit of detection alone does not tell how well this assay performs at a clinically relevant threshold. A very sound mathematical analysis of this issue was performed by Butturini et al. Ross et al. rightly state that the gold standard for MRD in acute leukemia is relapse. Therefore, studies that simultaneously apply various methods of monitoring MRD and determine which method is best at predicting relapse are strongly needed. Glucocorticoid(GC)-induced apoptosis is an essential component in the treatment of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL). Determining the extent of GC sensitivity/resistance has considerable clinical implications as it might be a relevant parameter in possible future patient-and tumor-adapted therapy regimens directed towards reducing the serious side effects of GC long-term therapy without affecting its anti-tumor efficacy. The most apical molecule in the GC-induced cell death pathway is the GC receptor (GR), a ligand-activated transcription factor of the large nuclear receptor family that, upon ligand binding translocates into the nucleus where it affects the expression of a large number of genes. 1 GR expression varies between different ALL cells and is further the subject of cell context-dependent positive and negative feedback regulation. 2 Although the apoptotic response clearly depends on the presence of a wild type GR, it is not understood to what extent differences in GR levels and GR auto-regulation influence sensitivity to GC-induced apoptosis.
GC resistance in in vitro models has been shown to result from mutations in the GR gene or lack of GR auto-induction 3 a phenomenon seen in several GC-sensitive ALL cell lines 2, 4 and some children with T-ALL. 5 GR mutations are however, rarely seen in samples from patients at relapse. 6 Whether basal GR levels and/or GR auto-induction might contribute to GC resistance in patients is controversial. In the older literature, GR levels correlated with treatment outcome in various lymphoid malignancies including ALL. More recently, one study showed that a higher number of GR binding sites was associated with a larger percent change in absolute peripheral blood blasts after a 3-day treatment with corticosteroids 7 but others concluded that GC sensitivity is independent of basal GR expression and/or GR auto-induction in childhood ALL patients. 8 To assess the role of GR expression levels and GR autoinduction on GC sensitivity we generated an in vitro model in which GR expression and regulation can be experimentally controlled. To this end, we first derived GC-resistant derivatives of the GC-sensitive CEM-C7H2-2C8 T-ALL cell line (that constitutively expresses a reverse tetracycline-activated transactivator protein, rtTA) by selection culture in 10 -6 M dexamethasone. One of them, termed CEM-C7H2-2C8-R42D9, was transduced with a lentiviral vector (pHR-tetCMV-hGR-ires-GFP) for tetracycline-regulated expression of human GR. Two stably transfected clonal derivatives were recovered, termed CEM-C7H2-2C8-R42D9-1B11 and CEM-C7H2-2C8-R42D9-1B10 (1B11 and 1B10, respectively), and analyzed further. Both clones behaved very similarly with respect to their response to GC in the absence and presence of doxycycline, so we focused our analyses on one of them, that is, 1B11. In the absence of the tetracycline analog doxycycline (that is, when the transgenic GR is not expressed), this cell line, like the GC-resistant parental CEM-C7H2-2C8-R42D9 cell line but unlike the GC-sensitive CEM-C7H2-2C8 and CEM-C7H2 progenitor lines, failed to auto-induce the GR or regulate classical GC response genes like FKBP51 or cyclin D3 (Figure 1a) . We next assessed to what extent the GR-ires-GFP transcript was regulated by doxycycline. Supplementary Figure  S1 shows that GFP expression was highly dependent on the amount of doxycycline and exposure time. Up to 6.25 ng/ml doxycycline failed to cause significant GFP induction over the investigated time (12 h to 10 days). Between 12.5 and 200 ng/ ml, the extent of induction increased over the first 5 days and remained at similar levels thereafter, whereas higher concentrations (400-3200 ng/ml) failed to further increase GFP expression. Immunoblotting experiments (Figure 1b ) revealed that GR expression was similarly doxycycline dose-and time-dependent and correlated well with that of GFP, as might be expected from a bi-cistronic mRNA. Moreover, GC regulation of FKBP51 and cyclin D3, two prominent GC response genes, was restored in 1B11 cells after induction of transgenic GR by doxycycline (Figure 1c) proving functionality of the transgenic GR. Thus, we had established a GC-resistant ALL model in which the expression of functional GR could be controlled at will.
Previous publications have shown that GC-induced apoptosis in CCRF-CEM cells is associated with, and dependent upon, GR auto-induction 4 and that GC resistance is frequently associated with, and caused by, lack of this positive GR feedback loop. 3 Two models may explain this phenomenon. First, GR autoinduction per se (that is, the increase in GR expression during Letters to the Editor the response) might be required, perhaps because different genes are regulated at low versus high GR levels and this sequence of gene regulations might be necessary for cell death induction. This model predicts that simply raising the GR level prior to dexamethasone exposure (that is, by pre-treatment with doxycycline) will not be sufficient to restore GC sensitivity. Rather, GR levels have to be gradually increased during the GC response to entail cell death (that is, the cells have to be treated with doxycycline and dexamethasone in parallel). The second model holds that basal GR levels (that is, prior to auto-induction) are too low in these cells to enable gene regulations required for cell death. However, as soon as cells reach the required GR threshold (as a result of auto-induction) they become able to initiate the death program. If true, this model predicts that simply raising basal GR levels would make the cells sensitive to GC-induced cell death (without requiring GR auto-induction). To distinguish between these two possibilities, doxycycline and dexamethasone (in different concentrations) were either administered simultaneously (Supplementary Figure S2A) , thereby mimicking the situation occurring in GC-sensitive CCRF-CEM derivatives (which show GR auto-induction), or doxycycline exposure was started 5 days in advance of GC treatment (Supplementary Figure S2B) to mimic the situation in cell lines that have higher basal GR expressions but lack GR autoinduction. Pre-treatment with doxycycline was at least as effective in restoring GC sensitivity as parallel addition of doxycycline and dexamethasone, arguing against the first model. Moreover, the data show a dramatic dependence of GC sensitivity on basal GR expression levels. Cells pretreated with up to 6.25 ng/ml doxycycline were resistant to all three dexamethasone concentrations (10, 100 and 1000 nM) even though GR was induced at low but detectable levels already at this doxycycline concentration ( Figure 2 shows the 48 h values, Supplementary Figure S2 the whole time course). At 12.5-25 ng/ml doxycycline, the response was dramatically dependent on the amount of dexamethasone, that is, almost no apoptosis was induced by 10 nM dexamethasone in cells treated with 12.5 ng/ml doxycycline but considerable (12.5 ng/ml doxycycline) to almost maximal (25 ng/ml doxycycline) levels by 100 or 1000 nM. By 50 ng/ml doxycycline (and higher concentrations of doxycycline) an almost complete cell death response was achieved with as little as 10 nM dexamethasone. Similar results were obtained with simultaneous administration of doxycycline and dexamethasone except that the response was somewhat retarded at the intermediate doxycycline concentrations (Supplementary Figure S2A ,12.5-100 ng/ml, 48 h). Thus, the combined data revealed a dramatic dependence of the GC dose required for apoptosis induction on the GR level in this childhood ALL model.
Next we asked whether the above observations occurred at GR levels similar to those seen in untransformed GC-sensitive CEM-C7H2 cells and more importantly, in lymphoblasts from ALL patients. To this end, identically prepared protein lysates from doxycycline-treated 1B11 cells, dexamethasone-treated CEM-C7H2 cells, and malignant lymphoblasts from children with precursor B-or T-ALL (prior to and after initiation of systemic GC monotherapy) 5 were size-separated on the same SDS-PAGE and immuno-blotted with antibodies against GR and a-tubulin as loading control (Supplementary Figure S3) . The signals obtained with the two antibodies were quantified and Letters to the Editor related to each other thereby deriving a-tubulin normalized GR levels. Although this analysis does not provide accurate quantification, it still suggested that the levels obtained with intermediate concentrations of doxycycline (12.5-50 ng/ml) were similar to those seen in CEM-C7H2 cells after 24 h of GC exposure or in at least some of the childhood ALL patients. Thus, the dramatic dependence of GC sensitivity on GR expression levels occurred at GR levels similar to those seen in malignant lymphoblasts from childhood ALL patients.
The combined data suggest that, within a defined cellular context, the expression levels of the GR determine kinetics and the extent of the apoptotic response in a dramatic manner. Within a narrow range of GR expression levels, we observed resistance to supra-pharmacological doses (1000 nM dexamethasone) and sensitivity to close to physiological GC concentrations (10 nM dexamethasone) (Figure 2 ). Given the differences in GR expression levels in childhood ALL samples also seen in this study (Supplementary Figure S3) , it seems likely that current protocols, which do not take into consideration GR levels, GR auto-induction or (rare but still occurring) GR mutations, are not optimal for each individual patient. However, since the death response depends on the cellular context as well, it is unlikely that assessing the absolute number of GR molecules alone (prior to, and ideally in the course of, GC exposure) will suffice to predict the GC dose required for an optimal therapeutic response in an individual patient. Future individualized protocols might therefore tailor the required GC dose based on the tumor's peculiarities (as reflected, for example, by its expression profile) and the status of its 'GC-GR rheostat'. Bruton's tyrosine kinase (Btk), which is important in B-cell development and activation, is a member of the Btk/Tec family of cytoplasmic tyrosine kinases, sharing a pleckstrin homology domain and Src homology SH3 and SH2 domains. 1,2 Btk has vital, but diverse, regulatory activities in various cellular processes. Among cell programs regulated by Btk there is apoptosis that can be either stimulated or inhibited by the kinase in different contexts. [1] [2] [3] The identification of molecular partners that can interact with Btk is required to individuate elements and understand mechanisms that regulate the kinase activity.
BAG3, a protein belonging to the BAG family of co-chaperones, interacts with heat-shock proteins (HSP) of the HSP70 family and other partners (phospholipase C-g, HspB8, and so on) through its BAG, WW and proline-rich (PXXP) domains. 4 Expression of BAG3 is induced in many normal cell types by stressful stimuli 4 and is constitutive in some tumor types, including leukemias, thyroid carcinomas and others, where BAG3 activity inhibits apoptosis. [4] [5] [6] [7] The prosurvival activity, displayed by BAG3 protein in human tumors, probably relies on different partnerships and/or mechanisms, depending on context. 4 Both Btk and BAG3 have been shown to modulate apoptosis and tumor growth in B-lymphoid neoplastic cells. 2, 3, 5, 6, 8 We therefore investigated whether the two proteins interacted in human B-lymphoma cells of the DeFew line. Cells were stimulated with b-phenylethyl isothiocyanate (PEITC) that induces oxidative stress; total lysates were obtained, immunoprecipitated with an anti-Btk antibody and analyzed with an anti-BAG3 antibody in immunoblotting. Although the BAG3 signal could not be detected in the immunoprecipitate from unstimulated cells, two bands were observed in the immunoprecipitate from PEITC-stimulated cells (Figure 1) . One of them was at the expected size of 75 kDa, whereas the other, upper band might correspond to a high molecular weight form of BAG3, sometimes detected in other cell systems and experimental conditions (unpublished observations).
